A detailed guide to supervised Spravato treatments in Indiana clinics, covering the mandatory two-hour observation period, safety protocols, and next-day recovery.
FDA Approval and Specified Indications
For adults exploring advanced options for severe depression, understanding the clinical process of supervised treatment is essential. Spravato (esketamine) is an FDA-approved prescription nasal spray designed for specific psychiatric indications. It is approved for use alongside a daily oral antidepressant in adults with treatment-resistant depression (TRD) and for treating depressive symptoms in adults with major depressive disorder (MDD) accompanied by acute suicidal ideation or behavior.
It is important to distinguish Spravato from IV ketamine, which is an FDA-approved anesthetic often utilized off-label for depression and other mental health conditions. The FDA has warned about the potential risks associated with unmonitored or compounded ketamine products, highlighting the necessity of receiving treatment in a certified clinical environment. Before beginning any regimen, a thorough consultation with a specialized healthcare provider is required to determine if Spravato is an appropriate intervention for your specific medical history.
The Certified Treatment Setting
Spravato is only available through a restricted distribution system called the Risk Evaluation and Mitigation Strategy (REMS) program. In Indiana, any healthcare facility that dispenses and administers Spravato must be REMS-certified. This certification ensures that the clinic is equipped to monitor patients safely and address any potential adverse reactions.
When you visit a certified location in Indiana, you will be treated in a designated medical space rather than taking the medication at home. The clinical environment is designed to maximize safety while providing a calm, supportive atmosphere during the therapeutic process.
The Treatment Process and Administration
The treatment session begins with a pre-administration check. Your healthcare provider will take your baseline vital signs, with a specific focus on your blood pressure, as Spravato can cause temporary increases in blood pressure. You will also be asked to confirm that you have followed the required fasting guidelines (typically avoiding food for two hours and liquids for 30 minutes before administration) and that your designated driver is confirmed for pickup.
Spravato is self-administered by the patient under the direct observation of a healthcare provider. The medication is delivered via a specialized nasal spray device. Your provider will instruct you on how to properly use the device to ensure you receive the correct dosage. Depending on the prescribed dose, you may use multiple devices, with a required resting period of five minutes between each use.
The Two-Hour Observation Period
Immediately following administration, you will begin a mandatory observation period that lasts for a minimum of two hours. This time is required by the REMS program to ensure patient safety. During this window, you will remain in a comfortable treatment room while clinical staff monitor you periodically.
Your blood pressure will be checked at specific intervals, typically around the 40-minute mark and again at the end of the two hours, to ensure it returns to a safe range. Providers also monitor for common side effects. Patients often experience dissociation (feeling disconnected from oneself, one's thoughts, or space and time), dizziness, nausea, sedation, and altered senses. Because these effects peak during the first hour and gradually subside, the two-hour observation window is critical for ensuring that you are stable before leaving the clinic.
Post-Treatment and Discharge
At the end of the two hours, your healthcare provider will evaluate your clinical status to determine if you are ready to be discharged. You will not be allowed to leave the clinic on your own. Because the medication can impair your cognitive and motor functions, driving or operating heavy machinery is strictly prohibited until the following day, after you have had a restful sleep.
You must be released into the care of a trusted adult who will drive you home. Patients are advised to spend the remainder of the day resting in a familiar, comfortable environment. Financial coverage for Spravato features variable coverage requiring individual confirmation with your insurance provider, so patients should coordinate with their clinic's billing department beforehand to understand their specific obligations.
For more detailed information regarding the clinical data and efficacy of these treatments, you can explore our research directory.
Source check date: November 4, 2026. This article is for educational purposes only and does not constitute medical advice.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.